Stockreport

PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device

PAVmed Inc.  (PAVM) 
US:NASDAQ Investor Relations: ir.pavm.com
PDF Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints NEW YORK, March 09, 2020 (GLOBE NEW [Read more]